{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:59:47Z","timestamp":1788649187101,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00228-025-03943-2","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T03:28:39Z","timestamp":1765942119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beta-blockers in acute decompensated heart failure with and without cardiogenic shock: Should we initiate, continue, or withdraw? A systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1814-5593","authenticated-orcid":false,"given":"Edinson Dante","family":"Meregildo-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3086-3408","authenticated-orcid":false,"given":"Karen Evelyn","family":"Ramos-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-2173","authenticated-orcid":false,"given":"Martha Genara","family":"Asmat-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-6430","authenticated-orcid":false,"given":"Gustavo Adolfo","family":"V\u00e1squez-Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3472-9997","authenticated-orcid":false,"given":"Mariano","family":"Ortiz-Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2488-9129","authenticated-orcid":false,"given":"Rossmery Kathereny","family":"Chochabot-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"3943_CR1","doi-asserted-by":"publisher","first-page":"102094","DOI":"10.1016\/j.jsps.2024.102094","volume":"32","author":"K Al Sulaiman","year":"2024","unstructured":"Al Sulaiman K, Alkofide HA, AlFaifi ME, Aljohani SS, Al Harthi AF, Alqahtani RA et al (2024) The concomitant use of ultra short beta-blockers with vasopressors and inotropes in critically ill patients with septic shock: a systematic review and meta-analysis of randomized controlled trials. Saudi Pharm J 32:102094\u2013102094. https:\/\/doi.org\/10.1016\/j.jsps.2024.102094","journal-title":"Saudi Pharm J"},{"key":"3943_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1448573","author":"GA V\u00e1squez-Tirado","year":"2024","unstructured":"V\u00e1squez-Tirado GA, Quispe-Casta\u00f1eda CV, Meregildo-Rodr\u00edguez ED, Cuadra-Campos M, Segura-Plasencia NM, Arbayza-Avalos YK et al (2024) Association of beta blockers and mortality in adults with septic shock: systematic review and meta-analysis of randomized clinical trial. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2024.1448573","journal-title":"Front Med (Lausanne)"},{"key":"3943_CR3","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e278","author":"M-S Ahn","year":"2020","unstructured":"Ahn M-S, Yoo B-S, Son J-W, Yu MH, Kang DR, Lee H-Y et al (2020) Beta-blocker therapy at discharge in patients with acute heart failure and atrial fibrillation. J Korean Med Sci. https:\/\/doi.org\/10.3346\/jkms.2020.35.e278","journal-title":"J Korean Med Sci"},{"key":"3943_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/jcdd8090101","volume":"8","author":"D Masarone","year":"2021","unstructured":"Masarone D, Martucci ML, Errigo V, Pacileo G (2021) The use of \u03b2-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 8:101\u2013101. https:\/\/doi.org\/10.3390\/jcdd8090101","journal-title":"J Cardiovasc Dev Dis"},{"key":"3943_CR5","doi-asserted-by":"publisher","unstructured":"Damluji AA, Forman DE, Wang TY, Chikwe J, Kunadian V, Rich MW et al Management of acute coronary syndrome in the older adult population: A scientific statement from the American heart association. Circulation 2023;147. https:\/\/doi.org\/10.1161\/CIR.0000000000001112","DOI":"10.1161\/CIR.0000000000001112"},{"key":"3943_CR6","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1038\/s41598-020-60528-y","volume":"10","author":"C Abi Khalil","year":"2020","unstructured":"Abi Khalil C, Zubaid M, Mekhaimar M, Asaad N, Mahfoud Z, Al Suwaidi J (2020) Beta-blockers and short-term cardiovascular outcomes in patients hospitalized for acute coronary syndrome and a left ventricular ejection fraction\u2009\u2265\u200940%. Sci Rep 10:3520\u20133520. https:\/\/doi.org\/10.1038\/s41598-020-60528-y","journal-title":"Sci Rep"},{"key":"3943_CR7","doi-asserted-by":"publisher","DOI":"10.2196\/11441","author":"R van Groenendael","year":"2019","unstructured":"van Groenendael R, Beunders R, Hofland J, Morshuis WJ, Kox M, van Eijk LT et al (2019) The safety, tolerability, and effects on the systemic inflammatory response and renal function of the human chorionic gonadotropin hormone-derivative EA-230 following on-pump cardiac surgery (the EASI study): protocol for a randomized, double-blind, placebo-controlled phase 2 study. JMIR Res Protoc. https:\/\/doi.org\/10.2196\/11441","journal-title":"JMIR Res Protoc"},{"key":"3943_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ejhf.3162","volume":"26","author":"M Riccardi","year":"2024","unstructured":"Riccardi M, Pagnesi M, Chioncel O, Mebazaa A, Cotter G, Gustafsson F et al (2024) Medical therapy of cardiogenic shock: contemporary use of inotropes and vasopressors. Eur J Heart Fail 26:411\u201331. https:\/\/doi.org\/10.1002\/ejhf.3162","journal-title":"Eur J Heart Fail"},{"key":"3943_CR9","doi-asserted-by":"publisher","first-page":"1263482","DOI":"10.3389\/fcvm.2023.1263482","volume":"10","author":"G Schurtz","year":"2023","unstructured":"Schurtz G, Mewton N, Lemesle G, Delmas C, Levy B, Puymirat E et al (2023) Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion. Front Cardiovasc Med 10:1263482. https:\/\/doi.org\/10.3389\/fcvm.2023.1263482","journal-title":"Front Cardiovasc Med"},{"key":"3943_CR10","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV13I2A21","author":"ER Bates","year":"2017","unstructured":"Bates ER (2017) Intravenous beta-blockers in patients with ST-elevation myocardial infarction treated with primary PCI. EuroIntervention. https:\/\/doi.org\/10.4244\/EIJV13I2A21","journal-title":"EuroIntervention"},{"key":"3943_CR11","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"3943_CR12","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/eurheartj\/ehp323","volume":"30","author":"G Jondeau","year":"2009","unstructured":"Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M et al (2009) B-CONVINCED: beta-blocker continuation vs. interruption in patients with congestive heart failure hospitalized for a decompensation episode. Eur Heart J 30:2186\u201392. https:\/\/doi.org\/10.1093\/eurheartj\/ehp323","journal-title":"Eur Heart J"},{"key":"3943_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s43044-024-00558-3","volume":"76","author":"CWD Sinardja","year":"2024","unstructured":"Sinardja CWD, Jagannatha GNP, de Liyis BG, Kosasih AM (2024) Safety and efficacy of early beta-blocker initiation in acute heart failure and cardiogenic shock: systematic review and meta-analysis. Egypt Heart J 76:126\u2013126. https:\/\/doi.org\/10.1186\/s43044-024-00558-3","journal-title":"Egypt Heart J"},{"key":"3943_CR14","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","volume":"73","author":"SJ Greene","year":"2019","unstructured":"Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM et al (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73:2365\u201383. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.015","journal-title":"J Am Coll Cardiol"},{"key":"3943_CR15","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G et al (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38:1883\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/ehx026","journal-title":"Eur Heart J"},{"key":"3943_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jama.289.6.712","volume":"289","author":"H Krum","year":"2003","unstructured":"Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJS et al (2003) Effects of initiating Carvedilol in patients with severe chronic heart failure. JAMA 289:712\u2013712. https:\/\/doi.org\/10.1001\/jama.289.6.712","journal-title":"JAMA"},{"key":"3943_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1161\/hc1002.105180","volume":"105","author":"SS Gottlieb","year":"2002","unstructured":"Gottlieb SS, Fisher ML, Kjekshus J, Deedwania P, Gullestad L, Vitovec J et al (2002) Tolerability of \u03b2-blocker initiation and titration in the Metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). Circulation 105:1182\u20131188. https:\/\/doi.org\/10.1161\/hc1002.105180","journal-title":"Circulation"},{"key":"3943_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jchf.2015.03.008","volume":"3","author":"KW Prins","year":"2015","unstructured":"Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S (2015) Effects of beta-blocker withdrawal in acute decompensated heart failure. JACC Heart Fail 3:647\u201353. https:\/\/doi.org\/10.1016\/j.jchf.2015.03.008","journal-title":"JACC Heart Fail"},{"key":"3943_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ejheart.2007.05.011","volume":"9","author":"M Metra","year":"2007","unstructured":"Metra M, Torp-Pedersen C, Cleland JGF, Di Lenarda A, Komajda M, Remme WJ et al (2007) Should beta\u2010blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 9:901\u20139. https:\/\/doi.org\/10.1016\/j.ejheart.2007.05.011","journal-title":"Eur J Heart Fail"},{"key":"3943_CR20","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 2022;145. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"key":"3943_CR21","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/S0735-1097(24)04381-X","volume":"83","author":"X Gao","year":"2024","unstructured":"Gao X, Liu M, Yang J, Yang Y (2024) The impact of initiation of oral beta-blockers during hospitalization on long-term outcomes in ST-elevation myocardial infarction patients with cardiogenic shock in real world setting: data from the China acute myocardial infarction (CAMI) registry. J Am Coll Cardiol 83:2391\u20132391. https:\/\/doi.org\/10.1016\/S0735-1097(24)04381-X","journal-title":"J Am Coll Cardiol"},{"key":"3943_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/J.CARDFAIL.2022.10.081","volume":"29","author":"W Parker","year":"2023","unstructured":"Parker W, Raby K, Hilton T, German C, Seals A, Withers K et al (2023) Blocked at the door: benefits of beta blockers in cardiogenic shock. J Card Fail 29:578\u2013578. https:\/\/doi.org\/10.1016\/J.CARDFAIL.2022.10.081","journal-title":"J Card Fail"},{"key":"3943_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13054-021-03706-2","volume":"25","author":"P Di Santo","year":"2021","unstructured":"Di Santo P, Mathew R, Jung RG, Simard T, Skanes S, Mao B et al (2021) Impact of baseline beta-blocker use on Inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial. Crit Care (London England) 25:289\u2013289. https:\/\/doi.org\/10.1186\/s13054-021-03706-2","journal-title":"Crit Care (London England)"},{"key":"3943_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.acvd.2019.04.004","volume":"112","author":"C Delmas","year":"2019","unstructured":"Delmas C, Orloff E, Bouisset F, Moine T, Citoni B, Biendel C et al (2019) Predictive factors for long-term mortality in miscellaneous cardiogenic shock: protective role of beta-blockers at admission. Arch Cardiovasc Dis 112:738\u201347. https:\/\/doi.org\/10.1016\/j.acvd.2019.04.004","journal-title":"Arch Cardiovasc Dis"},{"key":"3943_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121740","author":"LS Cardelli","year":"2023","unstructured":"Cardelli LS, Cherbi M, Huet F, Schurtz G, Bonnefoy-Cudraz E, Gerbaud E et al (2023) Beta blockers improve prognosis when used early in patients with cardiogenic shock: an analysis of the FRENSHOCK multicenter prospective registry. Pharmaceuticals (Basel, Switzerland). https:\/\/doi.org\/10.3390\/ph16121740","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"3943_CR26","first-page":"252","volume":"23","author":"R Ryu","year":"2021","unstructured":"Ryu R, Hauschild C, Bahjri K, Tran H (2021) Potential role of concomitant beta-blockers with vasopressors and inotropes in cardiogenic shock. Eur J Clin Pharm 23:252\u2013257","journal-title":"Eur J Clin Pharm"},{"key":"3943_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/medsci10040064","volume":"10","author":"R Ryu","year":"2022","unstructured":"Ryu R, Hauschild C, Bahjri K, Tran H (2022) The usage of concomitant beta-blockers with vasopressors and inotropes in cardiogenic shock. Med Sci 10:64\u201364. https:\/\/doi.org\/10.3390\/medsci10040064","journal-title":"Med Sci"},{"key":"3943_CR28","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"3943_CR29","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"3943_CR30","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions (2023) n.d. https:\/\/training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"3943_CR31","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","volume":"22","author":"G Knapp","year":"2003","unstructured":"Knapp G, Hartung J (2003) Improved tests for a random effects meta-regression with a single covariate. Stat Med 22:2693\u20132710. https:\/\/doi.org\/10.1002\/sim.1482","journal-title":"Stat Med"},{"key":"3943_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jchf.2020.09.005","volume":"8","author":"BN Tehrani","year":"2020","unstructured":"Tehrani BN, Truesdell AG, Psotka MA, Rosner C, Singh R, Sinha SS et al (2020) A standardized and comprehensive approach to the management of cardiogenic shock. JACC Heart Fail 8:879\u201391. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.005","journal-title":"JACC Heart Fail"},{"key":"3943_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13613-024-01260-y","volume":"14","author":"D Laghlam","year":"2024","unstructured":"Laghlam D, Benghanem S, Ortuno S, Bouabdallaoui N, Manzo-Silberman S, Hamzaoui O et al (2024) Management of cardiogenic shock: a narrative review. Ann Intensiv Care 14:45\u201345. https:\/\/doi.org\/10.1186\/s13613-024-01260-y","journal-title":"Ann Intensiv Care"},{"key":"3943_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bja.2019.08.015","volume":"123","author":"A Granholm","year":"2019","unstructured":"Granholm A, Alhazzani W, M\u00f8ller MH (2019) Use of the GRADE approach in systematic reviews and guidelines. Br J Anaesth 123:554\u2013559. https:\/\/doi.org\/10.1016\/j.bja.2019.08.015","journal-title":"Br J Anaesth"},{"key":"3943_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2046-4053-3-82","volume":"3","author":"N Meader","year":"2014","unstructured":"Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M et al (2014) A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev 3:82. https:\/\/doi.org\/10.1186\/2046-4053-3-82","journal-title":"Syst Rev"},{"key":"3943_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504735","author":"B Ibanez","year":"2025","unstructured":"Ibanez B, Latini R, Rossello X, Dominguez-Rodriguez A, Fern\u00e1ndez-Vazquez F, Pelizzoni V et al (2025) Beta-blockers after myocardial infarction without reduced ejection fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2504735","journal-title":"N Engl J Med"},{"key":"3943_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505985","author":"J Munkhaugen","year":"2025","unstructured":"Munkhaugen J, Kristensen AMD, Halvorsen S, Holmager T, Olsen MH, Bakken A et al (2025) Beta-blockers after myocardial infarction in patients without heart failure. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2505985","journal-title":"N Engl J Med"},{"key":"3943_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/MCC.0000000000001065","volume":"29","author":"JC Jentzer","year":"2023","unstructured":"Jentzer JC, Baran DA (2023) The changing face of cardiogenic shock: definitions, epidemiology, and severity assessment. Curr Opin Crit Care 29:363\u2013370. https:\/\/doi.org\/10.1097\/MCC.0000000000001065","journal-title":"Curr Opin Crit Care"},{"key":"3943_CR39","doi-asserted-by":"publisher","first-page":"786","DOI":"10.5603\/KP.a2017.0094","volume":"75","author":"KU Mert","year":"2017","unstructured":"Mert KU, Mert G\u00d6, Morrad B, Tahmazov S, Mutlu F, \u00c7avu\u015foglu Y (2017) Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias. Kardiol Pol 75:786\u2013793. https:\/\/doi.org\/10.5603\/KP.a2017.0094","journal-title":"Kardiol Pol"},{"key":"3943_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","volume":"52","author":"GC Fonarow","year":"2008","unstructured":"Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH et al (2008) Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 52:190\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2008.03.048","journal-title":"J Am Coll Cardiol"},{"key":"3943_CR41","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.cjca.2018.05.005","volume":"34","author":"MS Cho","year":"2018","unstructured":"Cho MS, Kim M-S, Lee SE, Choi H-I, Lee J-B, Cho H-J et al (2018) Outcomes after predischarge initiation of \u03b2-Blocker in patients hospitalized for severe decompensated heart failure requiring inotropic therapy. Can J Cardiol 34:1145\u201352. https:\/\/doi.org\/10.1016\/j.cjca.2018.05.005","journal-title":"Can J Cardiol"},{"key":"3943_CR42","doi-asserted-by":"publisher","first-page":"828614","DOI":"10.3389\/fcvm.2022.828614","volume":"9","author":"M Wang","year":"2022","unstructured":"Wang M, Liu J, Liu J, Hao Y, Yang N, Liu T et al (2022) Association between early oral \u03b2-Blocker therapy and In-Hospital outcomes in patients with ST-Elevation myocardial infarction with Mild-Moderate heart failure: findings from the CCC-ACS project. Front Cardiovasc Med 9:828614. https:\/\/doi.org\/10.3389\/fcvm.2022.828614","journal-title":"Front Cardiovasc Med"},{"key":"3943_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/FJC.0000000000001412","volume":"81","author":"L Lacoursiere","year":"2023","unstructured":"Lacoursiere L, Woodruff AE, Mills K, Chilbert MR (2023) A retrospective review of cardiogenic shock development in patients with ST-elevation myocardial infarction and percutaneous coronary intervention receiving early beta-blockers. J Cardiovasc Pharmacol 81:355\u2013360. https:\/\/doi.org\/10.1097\/FJC.0000000000001412","journal-title":"J Cardiovasc Pharmacol"},{"key":"3943_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/10742484241264673","author":"S Sun","year":"2024","unstructured":"Sun S, Han X, Bai L, Jeong MH, Jin C (2024) Beyond \u03b2-blockade: ACE inhibitors reduce non-cardiac mortality in high Killip grade AMI patients. J Cardiovasc Pharmacol Ther. https:\/\/doi.org\/10.1177\/10742484241264673","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"3943_CR45","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/CCM.0b013e31820a91ed","volume":"39","author":"M B\u00f6hm","year":"2011","unstructured":"B\u00f6hm M, Link A, Cai D, Nieminen MS, Filippatos GS, Salem R et al (2011) Beneficial association of \u03b2-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial*. Crit Care Med 39:940\u20134. https:\/\/doi.org\/10.1097\/CCM.0b013e31820a91ed","journal-title":"Crit Care Med"},{"key":"3943_CR46","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.jacc.2006.03.030","volume":"47","author":"J Butler","year":"2006","unstructured":"Butler J, Young JB, Abraham WT, Bourge RC, Adams KF, Clare R et al (2006) Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 47:2462\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2006.03.030","journal-title":"J Am Coll Cardiol"},{"key":"3943_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020012","author":"Y Tamaki","year":"2021","unstructured":"Tamaki Y, Yaku H, Morimoto T, Inuzuka Y, Ozasa N, Yamamoto E et al (2021) Lower in-hospital mortality with beta\u2010blocker use at admission in patients with acute decompensated heart failure. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.120.020012","journal-title":"J Am Heart Assoc"},{"key":"3943_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/eurjhf\/hfn008","volume":"11","author":"F Orso","year":"2009","unstructured":"Orso F, Baldasseroni S, Fabbri G, Gonzini L, Lucci D, D\u2019Ambrosi C et al (2009) Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian survey on acute heart Failure\u2020. Eur J Heart Fail 11:77\u201384. https:\/\/doi.org\/10.1093\/eurjhf\/hfn008","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03943-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:39:17Z","timestamp":1771508357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03943-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3943"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03943-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements & declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval declaration"}},{"value":"All authors affirm that we have not used any type of AI in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use or non-use of some form of AI"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Table S1: Search strategy; Table S2: Excluded studies; Table S3: Meta-regression analysis of the studies included in the metanalysis; Table S4: GRADE assessment. Figure\n                      \n                      a-S1c: Sensitivity analysis and Influence analysis of the studies included in the metanalysis; Figure S2a: Forest plot of the subgroup analysis according to the Study design Region (RCT or observational study) of the studies assessing the effect of BBs on clinical outcomes of CS; Figure S2b: Forest plot of the subgroup analysis, according to the Continent of origin of the studies assessing the effect of BBs on clinical outcomes of CS; Figure S2c: Forest plot of the subgroup analysis according to the year of publication of the studies assessing the effect of BBs on clinical outcomes of CS.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Supplementary materials"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}